These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6805621)

  • 41. Trough and peak effects of a single daily dose of nifedipine gastrointestinal therapeutic system (GITS) as assessed by ambulatory blood pressure monitoring. Italian Nifedipine GITS Study Group.
    Zanchetti A
    J Hypertens Suppl; 1994 Jul; 12(5):S23-7. PubMed ID: 7965282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Studies with prazosin--a new effective hypotensive agent. III. An acute double-blind cross-over study comparing the effects of single doses of prazosin and hydrallazine in combination with propranolol and a diuretic.
    Hua AS; Myers JB; Kincaid-Smith P
    Med J Aust; 1978 Jan; 1(1):45-8. PubMed ID: 368538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.
    Persson I
    Adv Clin Pharmacol; 1976; 11():1114-8. PubMed ID: 802071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antihypertensive action of drug combination: Timolol, hydralazine, hydrochlorothiazide and triamterene.
    Pörsti P; Jalonen K; Ryysy L; Toivonen T; Viherkoski M
    Ann Clin Res; 1981 Feb; 13(1):6-10. PubMed ID: 7018363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic.
    McAreavey D; Ramsey LE; Latham L; McLaren AD; Lorimer AR; Reid JL; Robertson JI; Robertson MP; Weir RJ
    Br Med J (Clin Res Ed); 1984 Jan; 288(6411):106-11. PubMed ID: 6419809
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Experience with a slow-release formulation of oxprenolol.
    Waal-Manning HJ; Spears GF
    N Z Med J; 1978 Apr; 87(609):245-6. PubMed ID: 275650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Once daily slow-release hydralazine in hypertension.
    O'Boyle CP; Kelly J; O'Brien ET; O'Malley K
    Ir Med J; 1981 Apr; 74(4):115-6. PubMed ID: 7228629
    [No Abstract]   [Full Text] [Related]  

  • 49. Hydralazine slow-release: observations on serum profile and clinical efficacy in man.
    Talseth T; Fauchald P; Pape JF
    Curr Ther Res Clin Exp; 1977 Feb; 21(2):157-68. PubMed ID: 403050
    [No Abstract]   [Full Text] [Related]  

  • 50. The safety and efficacy of once-daily nifedipine coat-core in combination with atenolol in hypertensive patients. Adalat CC Cooperative Study Group.
    Mac Carthy EP; Pettis PP; Gibson L; Schwartz L; Feig PU
    Clin Ther; 1993; 15(6):976-87. PubMed ID: 8111817
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination hypotensive therapy with atenolol, bendrofluazide and hydrallazine.
    Wilcox RG
    Postgrad Med J; 1977; 53 Suppl 3():128-33. PubMed ID: 337267
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison of a long-acting form of propranolol and conventional propranolol in the treatment of hypertension in elderly patients.
    Khan AU
    J Int Med Res; 1987; 15(3):128-33. PubMed ID: 3301452
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determinants of response to intravenous hydralazine in hypertension.
    Shepherd A; Lin MS; McNay J; Ludden T; Musgrave G
    Clin Pharmacol Ther; 1981 Dec; 30(6):773-81. PubMed ID: 7307426
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension.
    Serlin MJ; Orme ML; MacIver M; Green GJ; Sibeon RG; Breckenridge AM
    Br J Clin Pharmacol; 1983 May; 15(5):519-27. PubMed ID: 6860527
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thrice-daily blood pressure readings on sotalol in the treatment of hypertension: once- versus twice-daily regimen.
    Parvinen I; Paukkala E
    J Clin Pharmacol; 1979; 19(8-9 Pt 2):533-9. PubMed ID: 489772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Propranolol given twice daily in hypertension.
    Berglund G; Andersson O; Hansson L; Olander R
    Acta Med Scand; 1973 Dec; 194(6):513-5. PubMed ID: 4204165
    [No Abstract]   [Full Text] [Related]  

  • 58. Relation of hydralazine plasma concentration to dosage and hypotensive action.
    Zacest R; Koch-Weser J
    Clin Pharmacol Ther; 1972; 13(3):420-5. PubMed ID: 5026380
    [No Abstract]   [Full Text] [Related]  

  • 59. Placebo-controlled, double-blind clinical trial of alprenolol in African hypertensive patients.
    Salako LA; Falase AO; Aderounmu AF
    Curr Med Res Opin; 1979; 6(5):358-63. PubMed ID: 396111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relative bioavailability of immediate- and sustained-release hydralazine formulations.
    Ludden TM; Rotenberg KS; Ludden LK; Shepherd AM; Woodworth JR
    J Pharm Sci; 1988 Dec; 77(12):1026-32. PubMed ID: 3244106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.